Literature DB >> 12464602

Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor.

Eric I Park1, Stephen M Manzella, Jacques U Baenziger.   

Abstract

The asialoglycoprotein-receptor (ASGP-R) located on liver parenchymal cells was originally identified and characterized on the basis of its ability to bind glycoproteins bearing terminal galactose (Gal) or N-acetylgalactosamine (GalNAc); however, endogenous ligands for the ASGP-R have not to date been definitively identified. We have determined that the rat ASGP-R specifically binds oligosaccharides terminating with the sequence Siaalpha2,6GalNAcbeta1,4GlcNAcbeta1,2Man. Bovine serum albumin chemically modified with 10-15 tetrasaccharides with the sequence Siaalpha2,6GalNAcbeta1,4GlcNAcbeta1,2Man is cleared from the blood of the rat with a half-life of <1 min by a receptor located in the liver. We have isolated the receptor and identified it as the ASGP-R. Furthermore, we have determined that subunit 1 of the ASGP-R accounts for the binding of terminal Siaalpha2,6GalNAcbeta. Based on the newly defined specificity of the rat ASGP-R we hypothesize that glycoproteins bearing structures that are selectively modified with terminal Siaalpha2,6GalNAcbeta and are released into the blood may be endogenous ligands for the rat ASGP-R.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464602     DOI: 10.1074/jbc.M210612200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Peptide-specific transfer of N-acetylgalactosamine to O-linked glycans by the glycosyltransferases β1,4-N-acetylgalactosaminyl transferase 3 (β4GalNAc-T3) and β4GalNAc-T4.

Authors:  Dorothy Fiete; Mary Beranek; Jacques U Baenziger
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 2.  Challenges in treating Pompe disease: an industry perspective.

Authors:  Hung V Do; Richie Khanna; Russell Gotschall
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  Follicle-Stimulating Hormone Glycobiology.

Authors:  George R Bousfield; David J Harvey
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

4.  Modulation of mannose and asialoglycoprotein receptor expression determines glycoprotein hormone half-life at critical points in the reproductive cycle.

Authors:  Yiling Mi; Angela Lin; Dorothy Fiete; Lindsay Steirer; Jacques U Baenziger
Journal:  J Biol Chem       Date:  2014-03-11       Impact factor: 5.157

5.  Lectin binding assays for in-process monitoring of sialylation in protein production.

Authors:  Weiduan Xu; Jianmin Chen; Glenn Yamasaki; John E Murphy; Baisong Mei
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

6.  The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc.

Authors:  Eric I Park; Yiling Mi; Carlo Unverzagt; Hans-Joachim Gabius; Jacques U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-14       Impact factor: 11.205

7.  Comparison of Follicle-Stimulating Hormone Glycosylation Microheterogenity by Quantitative Negative Mode Nano-Electrospray Mass Spectrometry of Peptide-N Glycanase-Released Oligosaccharides.

Authors:  George R Bousfield; Vladimir Y Butnev; William K White; Aaron Smalter Hall; David J Harvey
Journal:  J Glycomics Lipidomics       Date:  2015

8.  The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose.

Authors:  Lindsay M Steirer; Eric I Park; R Reid Townsend; Jacques U Baenziger
Journal:  J Biol Chem       Date:  2008-12-15       Impact factor: 5.157

Review 9.  Sweet complementarity: the functional pairing of glycans with lectins.

Authors:  H-J Gabius; J C Manning; J Kopitz; S André; H Kaltner
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

10.  Ablation of GalNAc-4-sulfotransferase-1 enhances reproduction by altering the carbohydrate structures of luteinizing hormone in mice.

Authors:  Yiling Mi; Dorothy Fiete; Jacques U Baenziger
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.